Nexstim’s Annual Report 2017 will be published on the Company’s website on Wednesday, March 7, 2018.
Company announcement, Helsinki, 13 December 2017, at 9 am
Nexstim (NXTMH:HEX, NXTMS:STO) (“Nexstim” or the “Company”), a medical technology company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic and diagnostic applications, will publish the following financial information in 2018:
The 2017 Financial Statements Release and Half-Yearly Report July-December 2017 (H2) on Wednesday, February 28, 2018. Half-Yearly Report January-June 2018 (H1) on Thursday, August 16, 2018.
Nexstim’s Annual Report 2017 will be published on the Company’s website on Wednesday, March 7, 2018.
The Annual General Meeting is tentatively scheduled to be held on Wednesday, March 28, 2018 at 10:00 am.
NEXSTIM PLC
Martin Jamieson, Chairman and CEO
Further information is available on the website www.nexstim.com or by contacting:
Nexstim +44 77 1516 3942
Martin Jamieson, Chairman and CEO martin.jamieson@nexstim.com
UB Securities Oy (Certified Adviser) +358 (0)9 2538 0246
Citigate Dewe Rogerson +44 (0)207 2822949
David Dible/Isabelle Andrews/Shabnam Bashir david.dible@citigatedewerogerson.com
About Nexstim Plc
Nexstim is a medical technology company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic (NBT® system) and diagnostic (NBS system) applications. Nexstim’s NBS system is the only FDA cleared and CE marked system based on navigated Transcranial Magnetic Stimulation (nTMS) for the pre-surgical mapping of the speech and motor cortices of the brain. Based on the same technology platform, the Company has developed the Navigated Brain Therapy (NBT®) which is CE marked in Europe for the treatment of stroke, major depression and chronic neuropathic pain.
Nexstim has received clearance from the FDA for marketing and commercial distribution of its NBT® system for the treatment of Major Depressive Disorder (MDD) and looks forward to introducing the NBT® system for this important indication during H1 2018.
The NBT® system is currently in a 60 patient, supplemental Phase III study, E-FIT trial, for its use in stroke rehabilitation. The trial is expected to complete in mid-2018, allowing Nexstim to file for FDA clearance. FDA clearance would allow Nexstim to start marketing and selling its NBT® system for stroke rehabilitation in the USA.
Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com
